Article Details

Cancer biotech ArriVent Biopharma files for a $100 million IPO - Renaissance Capital

Retrieved on: 2024-01-05 21:48:51

Tags for this article:

Click the tags to see associated articles and topics

Cancer biotech ArriVent Biopharma files for a $100 million IPO - Renaissance Capital. View article details on hiswai:

Excerpt

ArriVent Biopharma, a Phase 3 biotech developing a novel kinase inhibitor for cancer, filed on Friday with the SEC to raise up to $100 million in ...

Article found on: www.renaissancecapital.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up